| [1] |
Pillebout E. Hepatorenal syndrome [J]. Nephrol Ther, 2014, 10(1): 61-68.
|
| [2] |
Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis [J]. Gut, 2007, 56(9): 1310-1318.
|
| [3] |
Prabhu MV, Sukanya B, Santosh PB, et al. The hepatorenal syndrome - a review] [J]. G Ital Nefrol, 2014, 31(3). pii: gin/31.3.12.
|
| [4] |
Barbano B, Sardo L, Gigante A, et al. Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs [J]. Curr Vasc Pharmacol, 2014, 12(1)：125-135.
|
| [5] |
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis [J]. J Hepatol, 2010, 53(3): 397-417.
|
| [6] |
Runyon B A. Management of adult patients with ascites due to cirrhosis: update 2012 [J/OL]. Hepatology，2013. DOI 10.1002/hep.00000. |
| [7] |
Verna EC, Brown RS, Farrand E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis [J]. Dig Dis Sci, 2012, 57(9): 2362-2370.
|
| [8] |
Gungor G, Ataseven H, Demir A, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study [J]. Liver Int, 2014, 34(1): 49-57.
|
| [9] |
Hasper D, Jorres A. New insights into the management of hepatorenal syndrome [J]. Liver Int, 2011, 31 (Suppl 3): 27-30.
|
| [10] |
Sola E, Cardenas A, Gines P. Results of pretransplant treatment of hepatorenal syndrome with terlipressin [J]. Curr Opin Organ Transplant, 2013, 18(3): 265-270.
|
| [11] |
Gluud LL, Christensen K, Christensen E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome [J]. Hepatology, 2010, 51(2): 576-584.
|
| [12] |
Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis [J]. Indian J Pharmacol, 2013, 45(1): 54-60.
|
| [13] |
Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin [J]．Transplantation, 2011, 91(10): 1141-1147.
|
| [14] |
Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1 [J]. Liver Transpl, 2011, 17(11): 1328-1332.
|
| [15] |
Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study [J]. Liver Int, 2013, 33(8): 1187-1193.
|
| [16] |
Sourianarayanane A, Raina R, Garg G, et al. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients [J]. Int Urol Nephrol, 2014, 46(4): 793-800.
|
| [17] |
Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome [J]. Hepatology, 2004, 40(1): 55-64.
|
| [18] |
Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice [J]. J Hepatol, 2012, 57(5): 1135-1140.
|